researchers and scientists from leading industry, academic, and government institutions… discuss innovation in drug development, target selection, and the impact of new discoveries in molecular and cell biology

More than 1000 participants attended the 16th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva.  The participants included various researchers and scientists from leading academic, industry, and government institutions.  Cancer was not the only topic presented at the symposium.  The findings of the asthma research conducted by the IDD were also presented.  STUDY DETAILS HERE

The IDD researchers include Dr. Sung Baek, Dr. David Campos, Dr. Armando Diaz, Dr. John Cornell, and Dr. Elzbieta Izbicka

Ask your most pressing medical and health questions at JBNI’s Team of Scientists and Physicians at http://jbni.us/forum or http://twitter.com/JBNIherbs . JBNI Genomics and Cancer Proteomics is the Maker of 100% Natural Bioprin. Bioprin is totally gentle on your stomach.

Dr. Sung Baek (aka Grand Master Sung Baek) along with his counterparts Dr. Robert Streeper and Dr. Elzbieta Izbicka, all of which are members of the Cancer Therapy and Research Center CTRC and The Institute for Drug Development IDD, have filed a patent that covers various methods of detection, identification, assessment, prevention, diagnosis, and treatment of lung disease, such as non-small cell cancer or reactive airway disease, using biomarkers and kits thereof. By comparing the biomarkers associated with the respiratory system pathologies to the biomarkers of a normal person’s serum, it is possible to detect the presence of the pathologies.

Currently, it is the presence or absence of a tumor that is noted and used in the diagnosis of lung cancer. Lung cancer is generally very hard to diagnose in its early stages. The difficulty to diagnose early plays a major factor in lung cancer patients’ low survival rates.

Reactive airway diseases, such as asthma and chronic obstructive pulmonary disease, is also diagnosed typically after a presentation of symptoms. After the symptoms arise the current methods to detect asthma are restricted to either function tests or challenge tests. A multitude of other test are often utilized to rule out other pathologies.

Dr. Sung Baek, Dr. Robert Streeper, and Dr. Elzbieta Izbicka, have identified a number of biomarkers which are useful in detecting lung diseases, such as non-small cell lung cancer or reactive airway disease. Their invention provides various diagnostic, prognostic and therapeutic methods, which depend on the identification of these biomarkers.

In Association with the IDD (Institute for Drug Development), Dr. Baek and his CPC (Cancer Prevention and Cure) team have also been honored to present their ongoing findings at many EORTC (European Organisation for Research and Treatment of Cancer) and AACR (American Association for Cancer Research) Annual Conferences.

For further information visit:

http://www.wipo.int/pctdb/en/wo.jsp?WO=2009036193

http://www.ctrc.net/ctrc_home.cfm?db_content=home&CFID=91108&CFTOKEN=98427686

http://docs.google.com/viewer?a=v&q=cache:pX0H91FxjjAJ:www.jbni.us/data/LuminexLungcancersingapore.pdf+jbni+streeper&hl=en&gl=us&sig=AHIEtbTrMwYEqX7JPBg8vRysbEcw43KaAw

http://btnsllc.com/Previous_Research.html

http://cancerres.aacrjournals.org/cgi/content/abstract/55/7/1491

http://74.125.155.132/search?q=cache:IhmWwLQutDMJ:www.ctrc.net/forms/pdf/IDDFactSheet.pdf+Dr.+Elzbieta+izbicka&cd=4&hl=en&ct=clnk&gl=us&client=firefox-a